Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries.
HIPEC
advanced gastric cancer
bidirectional chemotherapy
cytoreductive surgery
intraperitoneal chemotherapy
peritoneal metastasis
Journal
Pleura and peritoneum
ISSN: 2364-768X
Titre abrégé: Pleura Peritoneum
Pays: Germany
ID NLM: 101710063
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
12
12
2019
accepted:
03
03
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
23
6
2020
Statut:
epublish
Résumé
A new treatment using bidirectional intraperitoneal (IP) and intravenous (IV) chemotherapy developed by Asiatic surgeons improves outcomes in patients with synchronous peritoneal metastasis (PM) from gastric cancer (GC). We enrolled six consecutive patients with unresectable PM from GC who underwent bidirectional chemotherapy using IP docetaxel and IV FOLFOX or LV5FU2. In one course, IP docetaxel 30 mg/m All patients completed one bidirectional cycle. The regimen was well tolerated. The median OS was 13 months [range 5-18], and the 1-year OS rate was 67%. After the first bidirectional cycle, the PCI decrease ≥25% of the initial value in four patients. A major histological response was observed in four patients. This is the first Western study and confirms the feasibility and safety of bidirectional treatment using IP and IV chemotherapy for patients with unresectable PM from GC, resulting in a 13-month median OS with limited morbidity. The decrease in PCI after one bidirectional cycle is promising.
Sections du résumé
BACKGROUND
BACKGROUND
A new treatment using bidirectional intraperitoneal (IP) and intravenous (IV) chemotherapy developed by Asiatic surgeons improves outcomes in patients with synchronous peritoneal metastasis (PM) from gastric cancer (GC).
METHODS
METHODS
We enrolled six consecutive patients with unresectable PM from GC who underwent bidirectional chemotherapy using IP docetaxel and IV FOLFOX or LV5FU2. In one course, IP docetaxel 30 mg/m
RESULTS
RESULTS
All patients completed one bidirectional cycle. The regimen was well tolerated. The median OS was 13 months [range 5-18], and the 1-year OS rate was 67%. After the first bidirectional cycle, the PCI decrease ≥25% of the initial value in four patients. A major histological response was observed in four patients.
CONCLUSIONS
CONCLUSIONS
This is the first Western study and confirms the feasibility and safety of bidirectional treatment using IP and IV chemotherapy for patients with unresectable PM from GC, resulting in a 13-month median OS with limited morbidity. The decrease in PCI after one bidirectional cycle is promising.
Identifiants
pubmed: 32566725
doi: 10.1515/pp-2019-0035
pii: pp-pp-2019-0035
pmc: PMC7292234
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20190035Informations de copyright
© 2020 Lo Dico et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Competing interests: Authors state no conflict of interest.
Références
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Br J Surg. 2011 Feb;98(2):287-92
pubmed: 21046680
J Clin Oncol. 2009 Jul 20;27(21):3465-71
pubmed: 19470932
J Surg Oncol. 2012 Jan;105(1):38-42
pubmed: 21882194
J Clin Oncol. 2018 Jul 1;36(19):1922-1929
pubmed: 29746229
Surg Endosc. 2016 Sep;30(9):3808-15
pubmed: 26659231
World J Surg Oncol. 2018 Mar 22;16(1):62
pubmed: 29566715
Eur J Surg Oncol. 2010 Dec;36(12):1131-8
pubmed: 20933363
Anat Rec (Hoboken). 2010 May;293(5):754-61
pubmed: 20186966
Cancer. 2013 Sep 15;119(18):3354-8
pubmed: 23798046
J Surg Oncol. 2009 Sep 15;100(4):311-6
pubmed: 19697437
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Medicine (Baltimore). 2016 Jul;95(28):e4261
pubmed: 27428238
Pleura Peritoneum. 2019 Mar 05;4(1):20180127
pubmed: 31198852
Int J Cancer. 2014 Feb 1;134(3):622-8
pubmed: 23832847
Arch Surg. 2004 Jan;139(1):20-6
pubmed: 14718269
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901
pubmed: 14676112
Eur J Surg Oncol. 2006 Aug;32(6):625-7
pubmed: 16822641
World J Gastrointest Oncol. 2010 Feb 15;2(2):85-97
pubmed: 21160926
Cancer. 2000 Jan 15;88(2):358-63
pubmed: 10640968
Curr Oncol. 2014 Feb;21(1):e129-36
pubmed: 24523610
Ann Oncol. 2010 Jan;21(1):67-70
pubmed: 19605503
Jpn J Clin Oncol. 2009 Jul;39(7):443-8
pubmed: 19395466
Anticancer Res. 2010 Apr;30(4):1335-9
pubmed: 20530449
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064
pubmed: 20238327
Ann Surg Oncol. 2010 Sep;17(9):2370-7
pubmed: 20336386
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
JAMA Oncol. 2017 Sep 1;3(9):1237-1244
pubmed: 28448662
Clin Cancer Res. 2017 Jul 26;:
pubmed: 28747339
Eur J Surg Oncol. 2006 Aug;32(6):661-5
pubmed: 16621433
Ann Oncol. 2011 Oct;22(10):2179-90
pubmed: 21339384
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
World J Surg Oncol. 2016 Sep 27;14(1):253
pubmed: 27678344
Eur Surg Res. 2011;47(4):254-9
pubmed: 22067579
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Cancer Chemother Pharmacol. 2013 May;71(5):1265-72
pubmed: 23423490
Eur J Cancer. 2009 Nov;45(17):3017-26
pubmed: 19765978
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Pleura Peritoneum. 2016 Dec 1;1(4):209-215
pubmed: 30911625
Lancet Oncol. 2004 Apr;5(4):219-28
pubmed: 15050953
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Cancer Treat Rep. 1978 Jan;62(1):1-11
pubmed: 626987
Ann Surg Oncol. 2014 Apr;21(4):1147-52
pubmed: 24356799
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
Surgery. 1996 Apr;119(4):437-44
pubmed: 8644010